Article

TGF-β activates Akt kinase via a microRNA-dependent amplifying circuit targeting PTEN

Gonda Diabetes Center, Beckman Research Institute of the City of Hope, Duarte, CA 91010, USA.
Nature Cell Biology (Impact Factor: 20.06). 07/2009; 11(7):881-9. DOI: 10.1038/ncb1897
Source: PubMed

ABSTRACT Akt kinase is activated by transforming growth factor-beta1 (TGF-beta) in diabetic kidneys, and has important roles in fibrosis, hypertrophy and cell survival in glomerular mesangial cells. However, the mechanisms of Akt activation by TGF-beta are not fully understood. Here we show that TGF-beta activates Akt in glomerular mesangial cells by inducing the microRNAs (miRNAs) miR-216a and miR-217, both of which target PTEN (phosphatase and tensin homologue), an inhibitor of Akt activation. These miRNAs are located within the second intron of a non-coding RNA (RP23-298H6.1-001). The RP23 promoter was activated by TGF-beta and miR-192 through E-box-regulated mechanisms, as shown previously. Akt activation by these miRs led to glomerular mesangial cell survival and hypertrophy, which were similar to the effects of activation by TGF-beta. These studies reveal a mechanism of Akt activation through PTEN downregulation by two miRs, which are regulated by upstream miR-192 and TGF-beta. Due to the diversity of PTEN function, this miR-amplifying circuit may have key roles, not only in kidney disorders, but also in other diseases.

Download full-text

Full-text

Available from: Mitsuo Kato, Jul 30, 2015
2 Followers
 · 
2,156 Views
  • Source
    • "Results in this study support the conclusion that miR-217 targets the KRAS in osteosarcoma. Interestingly, miR-217 plays contrasting roles in cancer depending on cancer type (Kato et al., 2009; Zhao et al., 2010). Herein, miR-217 is a tumor suppressor which inhibits cell proliferation and metastasis in osteosarcoma. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Quercetin can suppress osteosarcoma cell growth and metastasis. However, other effects of quercetin on osteosarcoma remain largely unknown. This research aims to evaluate the effects of quercetin in combination with cisplatin as treatment for osteosarcoma and investigate its regulatory mechanism. Cell viability and apoptosis in 143B cell line were determined after treatment with quercetin and/or cisplatin. RT-PCR and Western blot analysis were performed to determine the RNA or protein expression levels. Moreover, transwell assay was used to evaluate metastasis. Furthermore, rescue experiments were performed to investigate the potential regulatory mechanism of the treatment. Results showed that quercetin with concentration that was equal to or greater than 10 μM inhibited 143B proliferation, while 5 μM quercetin enhanced the cisplatin sensitivity of 143B cells. Expression of miR-217 was upregulated after quercetin and/or cisplatin treatment, while its target KRAS was downregulated both at mRNA and protein levels. MiR-217 knockdown led to the loss of enhanced cisplatin sensitivity while miR-217 overexpression showed the opposite effects, indicating that quercetin regulated cisplatin sensitivity by modulating the miR-217-KRAS axis. In conclusion, 5 μM quercetin enhanced the cisplatin sensitivity by modulating the miR-217-KRAS axis. This finding suggests that quercetin may be administered with cisplatin to improve the treatment for osteosarcoma.
    Moleculer Cells 06/2015; DOI:10.14348/molcells.2015.0037 · 2.24 Impact Factor
  • Source
    • "Liu et al. demonstrated the pathogenic inter-relation between miR-21 and the fibrogenic growth factor TGF-b 1 [2]. TGF-b 1 is also known to modulate the transcription of microRNAs [3] and their maturation via activation of Smad proteins [4]. Due to their critical biological roles in fine tuning cellular and tissue homeostasis, we investigated the possible involvement of microRNAs in radiation enteropathy by molecular profiling and showed robust induction of miR-210 in a validated cellular model of radiation-induced fibrosis [5] [6] comprised of primary smooth muscle cells derived from human radiation enteropathy compared with their healthy counterparts (Fig 1A). "
    [Show abstract] [Hide abstract]
    ABSTRACT: A previously undescribed and robust miR210 overexpression is shown in intestinal samples obtained from patients with radiation enteropathy and fibrotic cultured cells. In addition, miR-210 overexpression is repressed by antifibrotic treatment combining pentoxifylline and α-tocopherol.
    Radiotherapy and Oncology 11/2013; 111(2). DOI:10.1016/j.radonc.2013.10.030 · 4.86 Impact Factor
  • Source
    • "miR-21 has been implicated in the immunopathogenesis of numerous inflammatory diseases [39]. Using an in vitro model of diabetes, Kato et al. showed that miR-21 overexpression in glucose-stimulated mesangial cells prevented cell proliferation by downregulating tumor suppressor phosphatase and tensin homolog (PTEN), whose 3 í® í° UTR contains a binding site for miR-21 [40] [41]. miR-21 expression is induced by STAT3, a transcription factor activated by IL-6. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by the deposition of immune complexes due to widespread loss of immune tolerance to nuclear self-antigens. Deposition in the renal glomeruli results in the development of lupus nephritis (LN), the leading cause of morbidity and mortality in SLE. In addition to the well-recognized genetic susceptibility to SLE, disease pathogenesis is influenced by epigenetic regulators such as microRNAs (miRNAs). miRNAs are small, noncoding RNAs that bind to the 3' untranslated region of target mRNAs resulting in posttranscriptional gene modulation. miRNAs play an important and dynamic role in the activation of innate immune cells and are critical in regulating the adaptive immune response. Immune stimulation and the resulting cytokine milieu alter miRNA expression while miRNAs themselves modify cellular responses to stimulation. Here we examine dysregulated miRNAs implicated in LN pathogenesis from human SLE patients and murine lupus models. The effects of LN-associated miRNAs in the kidney, peripheral blood mononuclear cells, macrophages, mesangial cells, dendritic cells, and splenocytes are discussed. As the role of miRNAs in immunopathogenesis becomes delineated, it is likely that specific miRNAs may serve as targets for therapeutic intervention in the treatment of LN and other pathologies.
    Clinical and Developmental Immunology 07/2013; 2013:430239. DOI:10.1155/2013/430239 · 2.93 Impact Factor
Show more